

Amendments to the Specification:

1. Please replace the abstract with the following amended abstract:

The tripeptide Tyrosyl-seryl-valine is disclosed with its use as a pharmaceutical composition in treating a condition whose effects can be reduced by stimulating T-cell transformation and a cell proliferative disorder. A method is also disclosed making a pharmaceutical composition comprising providing the tripeptide Tyrosyl-seryl-valine and mixing said tripeptide with a pharmaceutical acceptable carrier.

2. Please replace the last paragraph of page 28 with the following amended paragraph:

Another method of the treatment is the use of liposomes as a means for delivering the specific nucleic acid to the cells in the human body. The nucleic acid (such as an expression vector containing a nucleic sequence that encodes peptides of ~~sequence ID- No-4~~ the present invention) is delivered in an environment that encourages cellular uptake and chromosomal incorporation as described in Gao, X. and Huang, L. (1995) Gene Ther 2, 710-722 and US 6,207,456. Alternatively, the peptide itself can be encapsulated in the liposome and delivered directly, using a method described in US 6,245,427. All the scientific publications and patents indicated above are incorporated herein by reference in their entireties.

Applicants hereby declare that the no new matter has been added.